Because sustained activation of NLRP3 inflammasome results in progression to chronic inflammatory diseases, autoimmune diseases, cardiometabolic diseases, cancer, neurological disorders, and others, NLRP3 inflammasome inhibition in acute phases became a therapeutic target [9,65,67,68]. This evidence concerns the gene NLRP3 and nervous system disorder.